Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)

期刊论文
出版模式：

开放获取
发表日期：

2024年10月1日

查看全文

Andrew J. Armstrong,
Amy Taylor,
Michael C. Haffner,
Wassim Abida,
Alan H. Bryce,
Lawrence I. Karsh,
Scott T. Tagawa,
Przemyslaw Twardowski,
Anthony V. Serritella,
Joshua M. Lang

摘要

Background/Objectives

Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer.

Subjects/Methods

In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023–2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.

Results/Conclusion

We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.